Work with thought leaders and academic experts in hematology

Companies can greatly benefit from collaborating with academic researchers in the field of Hematology. These experts bring a wealth of knowledge and experience that can enhance research, development, and innovation in various ways. Here are some key reasons why companies would want to collaborate with Hematology researchers: 1. Cutting-edge Research: Hematology researchers are at the forefront of scientific advancements in blood disorders and diseases. Collaborating with them can provide access to the latest research findings and breakthroughs. 2. Expertise in Clinical Trials: Hematology researchers have extensive experience in conducting clinical trials for new treatments and therapies. Partnering with them can accelerate the development and testing of new drugs. 3. Access to Specialized Equipment: Hematology researchers often have access to state-of-the-art equipment and facilities. Collaborating with them can provide companies with access to advanced technologies for research and development. 4. Collaboration on Publications: Working with Hematology researchers can lead to joint publications in reputable scientific journals. This can enhance the company's reputation and credibility in the field. 5. Networking Opportunities: Collaborating with Hematology researchers allows companies to expand their professional network and establish connections with other experts in the field. By collaborating with academic researchers in Hematology, companies can tap into a vast pool of knowledge and expertise, leading to improved research outcomes and potential commercial success.

Researchers on NotedSource with backgrounds in hematology include Dushani L. Palliyaguru, Ph.D., Ping Luo, Burcu Vitrinel, Ph.D., Dr. Everson A Nunes, Ph.D., Boris Leibovitch, John M Baust, Ph.D, Jeffrey Townsend, Khoa Nguyen, Dr. Matthias Steiert, Ph.D., Luke Connelly, Marina Baretti, Michael Cukan, and Ritika Rastogi, PhD.

Ping Luo

Toronto, Ontario, Canada
Bioinformatics Specialist at Princess Margaret Cancer Centre with experience in deep learning
Most Relevant Research Interests
Hematology
Other Research Interests (21)
single-cell genomics
deep learning
complex network analysis
Genetics (clinical)
Genetics
And 16 more
About
8 years of science and engineering experience integrating multi-omics data to identify biomarkers for cancer studies. Seeking to apply data analytics expertise to develop new diagnosis and treatment strategies.
Most Relevant Publications (1+)

23 total publications

Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma

Blood / Nov 05, 2021

Coffey, D. G., Maura, F., Gonzalez-Kozlova, E., Diaz-Mejia3, J., Luo, P., Zhang, Y., Xu, Y., Warren, E. H., Smith, E. L., Cho, H. J., Lesokhin, A., Diamond, B., Kazandjian, D., Pugh, T. J., Green, D. J., Gnjatic, S., & Landgren, O. (2021). Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma. Blood, 138(Supplement 1), 329–329. https://doi.org/10.1182/blood-2021-154506

See Full Profile

Dr. Everson A Nunes, Ph.D.

Hamilton, Ontario, Canada
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Interests
Hematology
Other Research Interests (39)
skeletal muscle
nutrition
physical activity
obesity
cancer
And 34 more
About
Dr. Everson A Nunes is a highly accomplished researcher and educator in the field of physiological sciences. He received his Ph.D. in Cellular and Molecular Biology with a focus on Physiological Sciences from Universidade Federal do Paraná in 2009, after completing a BSc in Human Nutrition and an MSc in Physiological Sciences. He also holds a specialization in Exercise Physiology and a BSc in Biological Sciences from Universidade Federal do Paraná. Dr. Nunes has a strong background in research, having completed two post-doctoral fellowships at McMaster University and Universidade Federal do Paraná. He has also held positions as an associate professor and assistant professor at Universidade Federal de Santa Catarina. He has published numerous articles in peer-reviewed journals, and his research focuses on the effects of exercise and nutrition on physiological processes in the human body. In addition to his research, Dr. Nunes is also a dedicated educator. He has taught at various universities in Brazil, including Universidade Federal de Santa Catarina, Universidade Gama Filho, Faculdades Integradas Espírita, Pontificia Universidade Católica do Paraná, and Faculdade do Litoral Sul. He is known for his dynamic teaching style and his ability to engage students in complex physiological concepts. Dr. Nunes is a member of several professional organizations, including the American Society for Nutrition, the Canadian Society of Exercise Physiology, the Canadian Nutrition Society and the Brazilian Society of Physiology. He is also a regular speaker at national and international conferences, sharing his expertise and research findings with colleagues and students. Overall, Dr. Nunes is a highly qualified and experienced professional in physiological sciences, metabolism, cancer and nutrition. His dedication to research and education makes him a valuable asset to any institution.
Most Relevant Publications (1+)

97 total publications

Effects of omega-3 fatty acids on regulatory T cells in hematologic neoplasms

Revista Brasileira de Hematologia e Hemoterapia / Jan 01, 2013

Betiati, D. da S. B., Oliveira, P. F. de, Camargo, C. de Q., Nunes, E. A., & Trindade, E. B. S. de M. (2013). Effects of omega-3 fatty acids on regulatory T cells in hematologic neoplasms. Revista Brasileira de Hematologia e Hemoterapia, 35(2). https://doi.org/10.5581/1516-8484.20130033

See Full Profile

John M Baust, Ph.D

Ithaca, New York, United States of America
Proven success in delivering best-in-class services across scientific, commercial and education environments.
Most Relevant Research Interests
Hematology
Other Research Interests (16)
Cell Biology
Biotechnology
Biomedical Engineering
Transplantation
Surgery
And 11 more
About
***Proven success in delivering best-in-class services across highly regulated scientific and commercial environments.*** * Resourceful, dynamic, and future-focused professional; equipped with strategic leadership, business, research, and academic expertise with career excellence in conducting in-depth research, leading multi-faceted R&D projects, and developing new products and treatments. * Dedicated, driven self-starter focused on developing innovative life changing technologies and procedures advancing the areas of cancer treatment, regenerative medicine and cell therapy.   * Substantial experience in providing oversight for medical device development, pre-clinical studies, cancer therapy, stem cell preservation, cell therapy, tissue engineering, and organ transplantation, etc. * Astute at establishing solid relationships with stakeholders and industry leaders to drive innovative ideas and lead collaborative efforts in pursuit of accomplishing long-term milestones. * Successful in delivering interactive academic instruction across higher education settings offering captivating lectures on Biology and Entrepreneurship courses in accordance with the organizational mission. * Accredited with authoring, managing, and executing multi-million dollar grants, corporate contracts * Accomplished author of numerous patents and high profile publications to disseminate essential research findings.
Most Relevant Publications (1+)

68 total publications

Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model

Cancer Control / Jan 01, 2018

Santucci, K. L., Baust, J. M., Snyder, K. K., Van Buskirk, R. G., & Baust, J. G. (2018). Dose Escalation of Vitamin D3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model. Cancer Control, 25(1), 107327481875741. https://doi.org/10.1177/1073274818757418

See Full Profile

Jeffrey Townsend

New Haven, CT
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Hematology
Other Research Interests (52)
Evolutionary Genomics
Microbiology
Infectious Diseases
Genetics
Cell Biology
And 47 more
About
Jeffrey Townsend is a Professor of Organismic and Evolutionary Biology at Yale University. He received his Ph.D. from Harvard University in 2002 and his Sc.B. from Brown University in 1994. He has been a teacher at St. Ann's School and an Assistant Professor at the University of Connecticut. He is currently the Elihu Professor of Biostatistics at Yale University.
Most Relevant Publications (3+)

207 total publications

Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia

Leukemia / Nov 11, 2022

Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function

Annals of Oncology / Jan 01, 2017

Choi, M., Kadara, H., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Wistuba, I. I. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89. https://doi.org/10.1093/annonc/mdw437

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

Annals of Oncology / Jan 01, 2017

Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Herbst, R. S. (2017). Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 28(1), 75–82. https://doi.org/10.1093/annonc/mdw436

See Full Profile

Khoa Nguyen

San Francisco, California, United States of America
Life Sciences Expert with 18-Year Experience in Immunology, Metabolism, Neuroscience, and Biotech Entrepreuneuship
Most Relevant Research Interests
Hematology
Other Research Interests (25)
Metabolic Physiology
Neuroimmunology
Oncology
Biochemistry
Molecular Biology
And 20 more
About
Dr. Nguyen is an experienced immunologist who specializes in studies of cellular and molecular mechanisms by which innate immunity and energy metabolic pathways regulate disease development. He has more than 15 years of experience in building innovative preclinical research programs to investigate neurological, metabolic, and inflammatory diseases as well as 7 years of experience in early stage biotechnology R&D (including drug screening, pharmacology and toxicology). His PhD thesis work at the intersection of immunology and metabolism resulted in the discovery of the critical role of innate immunity in the development of metabolic diseases. These findings were highlighted in two seminal publications in Nature and Science and a series of other publications in high profile journals such as Cell, Nature Immunology, Nature Medicine, and Nature Reviews Immunology; and are of great clinical interest with regard to the understanding of the complex pathways that contribute to metabolic syndromes as well as the development of new cures for the treatment of these disorders. In his post-graduate career, Dr. Nguyen applied his technical expertise in cellular immunology and molecular biology; and his knowledge-based strength in innate immunity and metabolism into the field of neurobiology. His pioneering neuro-immunology research program in the last seven years led to the discovery of the role of distinct metabolic pathways in innate immune cells of the brain in the development of neurological diseases. Propelled by these exciting findings was the development of drug candidates to treat neuroinflammation and neurodegeneration, which is currently moving toward clinical development stage for the treatment of Amyotrophic Lateral Sclerosis and Multiple Sclerosis by Tranquis Therapeutics, an early-stage biotechnology company, of which Dr. Nguyen is a scientific founder.
Most Relevant Publications (1+)

47 total publications

Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways

Blood / Apr 07, 2011

Nguyen, K. D., Macaubas, C., Nadeau, K. C., Truong, P., Yoon, T., Lee, T., Park, J. L., & Mellins, E. D. (2011). Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways. Blood, 117(14), 3793–3798. https://doi.org/10.1182/blood-2010-11-318832

See Full Profile

Dr. Matthias Steiert, Ph.D.

Consultant with 30 years of interdisciplinary R&D experience in drug discovery and material sciences
Most Relevant Research Interests
Hematology
Other Research Interests (27)
nanomedicine
biomaterials
antimicrobials
cancer
biosensors
And 22 more
About
Matthias Steiert has extensive experience with nano-scale systems both for the development of drug delivery systems and diagnostics particularly in the areas of cancer and antimicrobial disease diagnostics. He is also a consultant for various companies involved in nanotechnological applications and is cofounder of Afaf Translations LLC, a scientific language service provider. Previously, he was co-founder of Los Gatos Pharmaceuticals and before held a position as Senior Director of R&D at Matrix Sensors Inc. and prior to that 10 years of senior-level research positions at several biotechnology companies in the fields of nanotechnology, drug development, diagnostics, and blood safety in the San Francisco Bay Area. Earlier in his career, Matthias was Senior Scientist at GlaxoSmithKline (Italy), a research fellow at the National Institute of Health and Environment (The Netherlands), and a consultant for the World Health Organization. He received his postdoctoral training from the University of California, Berkeley. Matthias holds a degree in plant physiology from the University of Freiburg (Germany) and obtained his Ph.D. in biochemistry from the University of Basel (Switzerland).
Most Relevant Publications (1+)

13 total publications

Photochemical inactivation with amotosalen and long‐wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components

Transfusion / Jul 29, 2008

Grellier, P., Benach, J., Labaied, M., Charneau, S., Gil, H., Monsalve, G., Alfonso, R., Sawyer, L., Lin, L., Steiert, M., & Dupuis, K. (2008). Photochemical inactivation with amotosalen and long‐wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion, 48(8), 1676–1684. Portico. https://doi.org/10.1111/j.1537-2995.2007.01762.x

See Full Profile

Luke Connelly

Professor of Health Economics, The University of Queensland, CBEH
Most Relevant Research Interests
Hematology
Other Research Interests (42)
Health economics
insurance
Public Health, Environmental and Occupational Health
Safety, Risk, Reliability and Quality
Human Factors and Ergonomics
And 37 more
About
Luke Connelly is Professor of Health Economics at the Centre for the Business and Economics of Health. He also holds a Professorial appointment (part-time) at The University of Bologna, to which he was appointed in 2017 via the Italian “Direct Call” ([link](https://www.unibo.it/sitoweb/luke.connelly/en)) process. In 2019 he was appointed as Honorary Professor at The University of Sydney. His main interests are in health economics and insurance economics and the effects of institutions (including legal constructs) on incentives and behaviour. He has also worked in other fields of applied microeconomics, including education economics and transport economics. His publications include papers in *Review of Income and Wealth*, *Health Economics*, *Journal of Health Economics*, *Journal of Risk and Insurance*, *Geneva Papers on Risk and Insurance*, *Accident Analysis and Prevention*, *Journal of Law and Medicine*, *Journal of Clinical Epidemiology*, *European Journal of Health Economics*, *International Journal of Health Economics and Finance*, *Social Science and Medicine*, *Economic Papers*, *Economic Analysis and Policy*, *Journal of Transport Economics and Policy*, *Labour Economics*, *Economics and Human Biology* as well as in a range of clinical journals, including *Lancet*. Luke has served on a number of public committees including the Medical Services Advisory Committee (MSAC), which advises the Australian Minister for Health on the safety, efficacy, effectiveness, and cost-effectiveness of new and extant listings on Australia's Medicare Benefits Schedule. He has extensive service on other public committees and taskforces as well as extensive teaching and consulting engagements with industry. Over his career he has been a chief investigator on research grants and contracts totalling more than $67m. He is a member of the Editorial Boards of European Journal of Health Economics and the International Journal on Environmental Research and Public Health. He is a member of the International Health Economics Association's Arrow Awards Committee, which awards an annual prize in honour of Nobel Laureate Kenneth Arrow for the best paper in the field. He is currently Guest Editor (with Christophe Courbage) on a Special Issue of the Geneva Papers on Risk and Insurance on Insurance and Emerging Health Risks. His current research interests include health service innovations to improve the health of people with chronic kidney disease(CKD). Ongoing interests include the economics of disability and insurance, compensable injury compensation schemes, and the determinants of health. Luke enjoys and has considerable experience teaching economics and health economics at both the graduate and undergraduate levels. In 2014 he was awarded the School of Economics Distinguished Teaching Award for his teaching on UQ's Master of Health Economics Program. In July 2016 and July 2019 he also taught summer schools in Health Economics and the Economics of Insurance at The University of Lucerne, Switzerland. Over the past 10 years he has been a chief investigator on grants totalling more than $70m.
Most Relevant Publications (1+)

105 total publications

An economic evaluation of plasma production via erythroplasmapheresis and whole blood collection

Transfusion and Apheresis Science / Oct 01, 2002

Connelly, L. B., & Pink, A. (2002). An economic evaluation of plasma production via erythroplasmapheresis and whole blood collection. Transfusion and Apheresis Science, 27(2), 101–111. https://doi.org/10.1016/s1473-0502(02)00046-0

See Full Profile

Marina Baretti

Baltimore, Maryland, United States of America
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Hematology
Other Research Interests (14)
Oncology
Pharmacology (medical)
Pharmacology
Gastroenterology
Hepatology
And 9 more
About
Throughout my training, I have been focused toward my ultimate goal of becoming a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions. My clinical research is centered on the development of novel agents in GI cancers, with particular interest in combinatorial approaches of epigenetic therapies and immunotherapies combinations. I ran the first phase II study of combination epigenetic therapy and immunotherapy in advanced pancreatic adenocarcinoma and cholangiocarcinoma, working with a collaborative team that incorporates leading experts in cancer immunology, epigenetics and drug development. I was awarded the 2018 ASCO Conquer Cancer Foundation Young Investigator Award for this project.  Together with Dr. Yarchoan, we are running a clinical trial of a novel neoantigen-specific vaccine in combination with immune checkpoint inhibitors for advanced fibrolamellar carcinoma (FLC) (NCT04248569). My laboratory focus has been on developing and validating a preclinical mouse model of FLC to investigate mechanisms underlying FLC pathogenesis, and will become a critical tool for investigating novel therapeutic strategies in FLC.
Most Relevant Publications (22+)

57 total publications

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram

Annals of Oncology / Mar 01, 2017

Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., … Cremolini, C. (2017). Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 28(3), 555–561. https://doi.org/10.1093/annonc/mdw627

Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic

Cancer Control / Jan 01, 2021

Jia, A. Y., Popovic, A., Mohan, A. A., Zorzi, J., Griffith, P., Kim, A. K., Anders, R. A., Burkhart, R. A., Lafaro, K., Georgiades, C., Azad, N. S., Liddell, R. P., Baretti, M., Kamel, I. R., Narang, A., Yarchoan, M., & Meyer, J. (2021). Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 28, 107327482110099. https://doi.org/10.1177/10732748211009945

Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)

Annals of Oncology / Oct 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of Oncology, 27, vi233. https://doi.org/10.1093/annonc/mdw371.84

Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer

Annals of Oncology / Sep 01, 2014

Sefrioui, D., Vasseur, C., Sesboué, R., Blanchard, F., Gangloff, A., Baretti, M., Beaussire, L., Clatot, F., Dolfus, C., Sabourin, J., Michel, P., Frebourg, T., & Di Fiore, F. (2014). Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer. Annals of Oncology, 25, iv559. https://doi.org/10.1093/annonc/mdu358.48

Modified Folfoxiri in advanced Pancreatic Cancer

Annals of Oncology / Sep 01, 2012

Ginocchi, L., Vasile, E., Caponi, S., Lucchesi, M., Caparello, C., Da Prat, V., Baretti, M., Lencioni, M., Ricci, S., & Falcone, A. (2012). Modified Folfoxiri in advanced Pancreatic Cancer. Annals of Oncology, 23, ix238. https://doi.org/10.1016/s0923-7534(20)33292-0

TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

Annals of Oncology / Sep 01, 2012

Borad, M., Reddy, S., Bahary, N., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W., Stephenson, J., Eng, C., & Ryan, D. P. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, 23, ix224. https://doi.org/10.1093/annonc/mds398

1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

Annals of Oncology / Sep 01, 2021

Heumann, T. R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T. Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C. D., O’Dwyer, P. J., Monga, D. K., Reiss Binder, K. A., & Azad, N. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology, 32, S1087–S1088. https://doi.org/10.1016/j.annonc.2021.08.797

Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram

Annals of Oncology / Sep 01, 2017

Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Morano, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., Miceli, R., & Aprile, G. (2017). Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Annals of Oncology, 28, v227. https://doi.org/10.1093/annonc/mdx369.052

ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND

Annals of Oncology / Oct 01, 2015

Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M. C., De Sanctis, R. M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology, 26, vi150. https://doi.org/10.1093/annonc/mdv348.59

SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus

Annals of Oncology / Oct 01, 2019

De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M. L., Alonso, V., Riesco Martinez, M. C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., & Viudez, A. (2019). SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Annals of Oncology, 30, v196. https://doi.org/10.1093/annonc/mdz245.006

Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study

Annals of Oncology / Oct 01, 2016

Baretti, M., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Rimassa, L., & Santoro, A. (2016). Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Annals of Oncology, 27, vi183. https://doi.org/10.1093/annonc/mdw370.104

Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study

Annals of Oncology / Sep 01, 2016

Baretti, M., Giordano, L., Rimassa, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Personeni, N., & Santoro, A. (2016). Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Annals of Oncology, 27, iv48. https://doi.org/10.1093/annonc/mdw335.29

An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort

Annals of Oncology / Sep 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort. Annals of Oncology, 27, iv25. https://doi.org/10.1093/annonc/mdw333.29

Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience

Annals of Oncology / Sep 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience. Annals of Oncology, 27, iv18. https://doi.org/10.1093/annonc/mdw333.03

P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer

Annals of Oncology / Jun 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer. Annals of Oncology, 27, ii51. https://doi.org/10.1093/annonc/mdw199.167

O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)

Annals of Oncology / Jun 01, 2016

Pietrantonio, F., Cremolini, C., Rimassa, L., Lonardi, S., Mennitto, A., Morano, F., Iacono, D., Berenato, R., Caporale, M., Niger, M., Marmorino, F., Bozzarelli, S., Bergamo, F., Rossini, D., Baretti, M., Battaglin, F., Bonotto, M., Loupakis, F., de Braud, F., & Miceli, R. (2016). O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 27, ii122. https://doi.org/10.1093/annonc/mdw198.13

Third-Line Folfiri in Metastatic Gastric Cancer Patients

Annals of Oncology / Sep 01, 2012

Caparello, C., Vasile, E., Lencioni, M., Fabrini, M. G., Lucchesi, M., Ginocchi, L., Caponi, S., Santi, S., Ricci, S., & Falcone, A. (2012). Third-Line Folfiri in Metastatic Gastric Cancer Patients. Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33344-5

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

See Full Profile

Ritika Rastogi, PhD

Boston, Massachusetts, United States of America
Brigham & Women's Hospital
Most Relevant Research Interests
Hematology
Other Research Interests (14)
race/ethnicity
mental health
youth studies
adolescent development
school contexts
And 9 more
Most Relevant Publications (1+)

8 total publications

A PDZ-Binding Motif in DCAF7 Maintains Hematopoietic Homeostasis and Prevents Malignancy in DS-AMKL

Blood / Dec 02, 2016

Kirsammer, G., Schultz, R. F., Rastogi, R., Gurbuxani, S., & Crispino, J. (2016). A PDZ-Binding Motif in DCAF7 Maintains Hematopoietic Homeostasis and Prevents Malignancy in DS-AMKL. Blood, 128(22), 1205–1205. https://doi.org/10.1182/blood.v128.22.1205.1205

See Full Profile

Example hematology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on hematology?

Development of Novel Hematology Diagnostic Tool

A company in the medical device industry can benefit from collaborating with a Hematology researcher to develop a novel diagnostic tool for blood disorders. The researcher's expertise in analyzing blood samples and identifying specific markers can contribute to the development of an accurate and efficient diagnostic device.

Drug Discovery for Hematological Cancers

A pharmaceutical company focused on oncology can collaborate with a Hematology researcher to discover new drugs for hematological cancers. The researcher's deep understanding of the molecular mechanisms involved in blood cancers can guide the development of targeted therapies.

Improving Blood Transfusion Practices

A healthcare organization can partner with a Hematology researcher to improve blood transfusion practices. The researcher's knowledge of blood compatibility, transfusion reactions, and storage techniques can help optimize transfusion protocols and ensure patient safety.

Development of Gene Therapies for Hemophilia

A biotechnology company can collaborate with a Hematology researcher to develop gene therapies for hemophilia. The researcher's expertise in gene editing and delivery systems can contribute to the development of innovative treatments for this genetic blood disorder.

Exploring Stem Cell Therapies for Blood Disorders

A regenerative medicine company can work with a Hematology researcher to explore the potential of stem cell therapies for blood disorders. The researcher's knowledge of hematopoietic stem cells and their differentiation can aid in developing novel therapeutic approaches.